GLAUKOS CORPORATION

Lobbying for GLAUKOS CORPORATION · Research and product development

Filing 1st Quarter - Report

Reporting period

1st Quarter 2025

Jan 1 - Mar 31 · Posted Apr 16, 2025

Expenses

$45,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

California

Official filing document

Bills named in this filing 5

HR 7024
Tax Relief for American Families and Workers Act of 2024
HR 8702
Improving Seniors’ Timely Access to Care Act of 2024
S 4532
Improving Seniors’ Timely Access to Care Act of 2024
HR 972
Outpatient Surgery Quality and Access Act of 2023
S 312
Outpatient Surgery Quality and Access Act of 2023

Lobbying activity 3

Taxation/Internal Revenue Code

Tax Relief for American Families and Workers Act of 2023 H.R. 7024

Medicare/Medicaid

H.R. 8702/S. 4532 Improving Seniors Timely Access to Care Act of 2024 H.R. 972/ S. 312 Outpatient Surgery Quality and Access Act of 2023

Medical/Disease Research/Clinical Labs

Legislation regarding FDA regulation of combination products

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.